Abivax CEO says $920M raise lets it launch its bowel disease drug in the U.S. solo
The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC
Read the full articleYou might also wanna read
Abivax sichert 920 Millionen Dollar und zeigt starke Phase-3-Daten zu Obefazimod
PARIS / LONDON (IT BOLTWISE) – Abivax hat 920 Millionen US-Dollar eingesammelt und untermauert damit die weitere Entwicklung von Obefazimod.
Abivax Aktie: 1.691 Prozent in zwölf Monaten
Fast jeder zweite Anteilsschein von Abivax befindet sich mittlerweile in den Depots institutioneller Investoren. Während der Kurs nach einer
‘CROWN JEWEL’: Pfizer CEO touts ‘TREMENDOUS SUCCESSES’ in oncology R&D
Pfizer CEO Albert Bourla details $70B US investment in manufacturing and R&D, discussing oncology advancements, the GLP-1 drug race, and AI’
Drugmakers Plan Price Increases on 350+ Medications Despite Government Pressure
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster
reuters.com·6mo agoRevolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
Evonik Aktie: 650 Millionen EBITDA im Q2 erwartet
Evonik schaltet in den Angriffsmodus. Der Spezialchemie-Konzern investiert massiv in den USA. Parallel dazu hebt die Führung ihre Gewinnziel
Comments
Sign in to join the conversation.
No comments yet. Be the first.